유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae-stam ms-h - immunologicals för aves, live bakteriella vacciner - kyckling - för aktiv immunisering av framtida könsuppfödarehönor, framtida lageruppfödarehönor och framtida lagerhönor för att minska sårskador och minska antalet ägg med onormal skalbildning orsakad av mycoplasma synoviae.

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

ebb medical ab - protaminsulfat - injektions-/infusionsvätska, lösning - 1400 anti-heparin ie/ml - protaminsulfat 1400 anti-heparin ie aktiv substans - protamin

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - protaminsulfat - injektions-/infusionsvätska, lösning - 1400 anti-heparin ie/ml - protaminsulfat 1400 anti-heparin ie aktiv substans - protamin

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - protaminsulfat - injektions-/infusionsvätska, lösning - 1400 anti-heparin ie/ml - protaminsulfat 1400 anti-heparin ie aktiv substans - protamin

유럽 연합 - 스웨덴어 - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

crucell italy s.r.l. - hepatit a-virus, stam rg-sb, inaktiverat antigen - injektionsvätska, suspension, förfylld spruta - hepatit a-virus, stam rg-sb, inaktiverat antigen 24 ie aktiv substans - inaktiverat helvirusvaccin

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

glenmark pharmaceuticals nordic ab - rivaroxaban - filmdragerad tablett - 2,5 mg - rivaroxaban 2,5 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

glenmark pharmaceuticals nordic ab - rivaroxaban - filmdragerad tablett - 10 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; rivaroxaban 10 mg aktiv substans

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

glenmark pharmaceuticals nordic ab - rivaroxaban - filmdragerad tablett - 15 mg - natriumlaurilsulfat hjälpämne; rivaroxaban 15 mg aktiv substans; laktosmonohydrat hjälpämne

스웨덴 - 스웨덴어 - Läkemedelsverket (Medical Products Agency)

glenmark pharmaceuticals nordic ab - rivaroxaban - filmdragerad tablett - 20 mg - rivaroxaban 20 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne